医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Frontier Health Corporation to Participate in UBS Virtual Global Healthcare Conference 2020

2020年05月18日 PM09:30
このエントリーをはてなブックマークに追加


 

BEIJING

New Frontier Health Corporation (“NFH” or “the Company”) (NYSE: NFH), operator of the premium healthcare services provider United Family Healthcare (“UFH”), today announced that its management team will participate in the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020, at 8:20 am U.S. Eastern Time.

A live webcast of management’s presentation will be available on the “Events & Presentations” section of the Company’s investor relations website at www.nfh.com.cn. A replay of the webcast will be available for 30 days.

About New Frontier Health Corporation

New Frontier Health Corporation (NYSE: NFH) is the operator of United Family Healthcare (UFH), a leading private healthcare provider offering comprehensive premium healthcare services in China through a network of private hospitals and affiliated ambulatory clinics. UFH currently has nine hospitals in operation or under construction in all four 1st tier cities and select 2nd tier cities. Additional information may be found at www.nfh.com.cn.

Source: New Frontier Health Corporation

View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005283/en/

CONTACT

Media

Harry Chang

Tel: +852-9822-1806

Email: harry@new-frontier.com

Wenjing Liu

Tel: +86-186-1151-5796

Email: liu.wenjing@ufh.com.cn

Investors

ICR, LLC

William Zima/Rose Zu

Tel: +1-203-682-8200

Email: bill.zima@icrinc.com/rose.zu@icrinc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
  • ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
  • ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
  • ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
  • Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML